Daily Archives: May 1, 2023
A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS
Neihulizumab (ALTB-168) is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), and leads to downregulation of activated T-cells. Early-phase trials of neihulizumab have suggested a benefit in patients with immune conditions… Continue reading
METABOLOMICS ANALYSIS IDENTIFIED AN ORALLY ACTIVE METABOLITE FOR TREATING CROHN’S DISEASE-ASSOCIATED INTESTINAL FIBROSIS
Intestinal fibrosis is a debilitating complication of Crohn’s disease (CD) patients. Surgical resection is used to treat intestinal strictures, but this approach may adversely affect the patients’ quality of life. Based on the findings of our groups an… Continue reading
EICOSATETRAYNOIC ACID REGULATES PRO-FIBROTIC PATHWAYS IN AN INDUCED PLURIPOTENT STEM CELL DERIVED MACROPHAGE:HUMAN INTESTINAL ORGANOID MODEL OF ILEAL CROHN’S DISEASE
Biologics targeting TNF are the mainstay of therapy for children with Crohn’s Disease (CD). However, a subset of patients do not respond, progressing to intestinal fibrosis requiring surgical resection. Prior studies have defined an ileal gene expressi… Continue reading
EXCESS DIETARY SUGAR ALTERS COLONOCYTE METABOLISM AND IMPAIRS THE EARLY PROLIFERATIVE RESPONSE TO DAMAGE
The colonic epithelium requires continuous renewal by crypt resident intestinal stem cells (ISCs) and transit amplifying (TA) cells to maintain barrier integrity, especially after inflammatory damage. An important regulator of ISC and TA cell function … Continue reading
SEX-BASED DIFFERENCES IN DRUG DURABILITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
With an increasing number of therapeutic options to treat IBD, identification of patient-specific factors predictive of drug efficacy is crucial. Sex has been postulated to play a role in response to therapy with possible proposed mechanisms including … Continue reading
EPITHELIAL CELLS OF ULCERATIVE COLITIS PATIENTS REQUIRE NORMAL LEVELS OF MITOCHONDRIA AND BETA-CATENIN TO UTILIZE BUTYRATE METABOLISM AND PROMOTE ULCER HEALING
Under normal conditions butyrate produced by obligate anaerobes (e.g. firmicutes) provides the dominant energy source for colonocytes via β-oxidation and the tricarboxylic acid cycle. Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) chara… Continue reading
DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME MEASURE FOR CROHN’S DISEASE: THE CROHN’S DISEASE-HEALTH INDEX (CD-HI), A FULLY VALIDATED TOOL TO BOLSTER CLINICAL TRIAL AND RESEARCH INFRASTRUCTURE
To bolster Crohn’s disease (CD) clinical trial and research infrastructure through the development and validation of a sensitive, multifactorial, disease-specific, patient-reported outcome measure (PRO) for patient monitoring in therapeutic trials of C… Continue reading
CREATINE KINASE EXPRESSION IS PROTECTIVE IN A MOUSE COLITIS MODEL
We have previously identified a loss of expression of creatine pathway proteins in mucosal tissue samples from inflammatory bowel disease patients. This is important as creatine is vital to ATP buffering in energetically active cells. The goal of this … Continue reading
INTESTINAL PERFORATIONS IN PATIENTS WITH IBD: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE 2015-2019
Inflammatory Bowel Disease results in numerous complications due to inflammatory damage to the intestinal mucosa. One complication of IBD is perforation of the intestines. The aim of our study was to study the impact of IBD on clinical outcomes in pati… Continue reading
COLITIS-ASSOCIATED COLON CANCER: EXPLORING THE DCLK1-S-MMP13-P53 AXIS
Chronic intestinal inflammation in patients with inflammatory bowel diseases (IBD) significantly increases the risk of colorectal cancer (CRC). Tuft cells in the intestine marked by doublecortin-like kinase-1 (DCLK1), are long-lived chemosensory cells … Continue reading